As adverse effects and P-gp activity in tumor cells are unlikely to be causally linked, these results may suggest that P-gp activity in cancer cells may be a surrogate marker of the patient’s capacity to excrete P-gp substrates through hepatic, renal, or intestinal clearance. This evidence concerns the gene PGP and cancer.